On June 10, WuXi XDC fell 3.18% in regular trading, trading at 44.54 HKD/share, with trading volume of 61.28 million HKD. The stock has now dropped over 22% below the company's earlier buyback average price of 57.3 HKD.

On the news front, the US Department of Defense updated its Section 1260H list on June 8, adding 188 entities including WuXi AppTec, the affiliate of WuXi XDC's parent company WuXi Biologics. While the list does not directly freeze assets or ban securities trading, it raises compliance screening risks among banks, carriers, and clients, and may lead to cross-referencing with other restrictive lists. Meanwhile, despite intensive buybacks totaling approximately 500 million USD across the WuXi group — including 327 million HKD spent repurchasing 5.702 million shares at an average of 57.3 HKD — selling pressure remains unabated. Today, the broader WuXi ecosystem continued to weaken, with WuXi Biologics down 2.81%, GenScript Biotech down 2.86%, and Pharmaron down 3.23%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)